BR0212366A - Método e composição para tratar distúrbios associados com o complexo imune - Google Patents

Método e composição para tratar distúrbios associados com o complexo imune

Info

Publication number
BR0212366A
BR0212366A BR0212366-5A BR0212366A BR0212366A BR 0212366 A BR0212366 A BR 0212366A BR 0212366 A BR0212366 A BR 0212366A BR 0212366 A BR0212366 A BR 0212366A
Authority
BR
Brazil
Prior art keywords
tlr
immune complex
icad
immune
cells
Prior art date
Application number
BR0212366-5A
Other languages
English (en)
Inventor
Ann Marshak-Rothstein
Elizabeth Leadbetter
Ian Rifkin
Original Assignee
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Boston filed Critical Univ Boston
Publication of BR0212366A publication Critical patent/BR0212366A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

"MéTODO E COMPOSIçãO PARA TRATAR DISTúRBIOS ASSOCIADOS COM COMPLEXO IMUNE". A presente invenção fornece métodos e composições para tratar doenças associadas com complexo imune (ICAD), tal como SLE, artrite reumatóide, e doenças do complexo imune relacionadas com hepatite c (por exemplo, crioglobulinemia) em um indivíduo tendo um ICAD ou em risco de desenvolver ICAD. A invenção é com base na surpreendente descoberta de que os complexos imune contendo cromatina ativam as células B e auto-reativas e dendríticas por um processo de comprometimento do receptor dual que, em ambos tipos de células, envolve um receptor tipo Toll (TLR). Os métodos de tratamento de ICAD compreendem administrar um composto à um indivíduo em necessidade deste que ou 1) inibe a formação do complexo imune ou por prevenção da formação e/ou aglutinação ao TLR, ou 2) interfere com a aglutinação de um complexo imune contendo auto-antígeno (ou o componente antigênico deste) ao TLR, ou 3) inibe as vias de sinalização iniciadas pelo comprometimento dual de BCR e TLR (nas células B) ou FcR e TLR (nas células dendríticas) através de auto-antígenos não complexos ou complexos imunes.
BR0212366-5A 2001-09-07 2002-09-09 Método e composição para tratar distúrbios associados com o complexo imune BR0212366A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31809601P 2001-09-07 2001-09-07
US36757802P 2002-03-26 2002-03-26
PCT/US2002/028708 WO2003022296A1 (en) 2001-09-07 2002-09-09 Method and composition for treating immune complex associated disorders

Publications (1)

Publication Number Publication Date
BR0212366A true BR0212366A (pt) 2004-07-27

Family

ID=26981316

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212366-5A BR0212366A (pt) 2001-09-07 2002-09-09 Método e composição para tratar distúrbios associados com o complexo imune

Country Status (12)

Country Link
US (2) US7709451B2 (pt)
EP (1) EP1435987A4 (pt)
JP (2) JP2005501917A (pt)
KR (1) KR20040053122A (pt)
CN (1) CN1575184A (pt)
AU (1) AU2002324937B2 (pt)
BR (1) BR0212366A (pt)
CA (1) CA2459310A1 (pt)
EA (1) EA200400407A1 (pt)
IL (1) IL160561A0 (pt)
NZ (1) NZ531612A (pt)
WO (1) WO2003022296A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4280309B2 (ja) * 1997-06-06 2009-06-17 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ｄｎａ免疫刺激配列活性の阻害剤
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
WO2006047954A1 (fr) * 2004-11-04 2006-05-11 Ziyi Cheng Procédé d'obtention et d'application des matières pour la reconnaissance immunologique d'autoantigènes
AR051836A1 (es) * 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
ES2348792T3 (es) * 2004-12-10 2010-12-14 Novimmune Sa TERAPIAS COMBINADAS DIRIGIDAS A MÚLTIPLES RECEPTORES TIPO TOLL Y USO DE LAS MISMAS.
CN100429233C (zh) * 2005-02-03 2008-10-29 上海长海医院 一种重组融合蛋白及其制备方法及用途
JP5199878B2 (ja) * 2005-10-27 2013-05-15 セントカー・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター、方法および用途
JP2010509398A (ja) * 2006-11-15 2010-03-25 ザ テキサス エー アンド エム ユニバーシティ システム Ｔｏｌｌ様受容体３に関連する組成物および方法
US8323656B2 (en) * 2007-06-25 2012-12-04 Yijun Xu Antigen determinant of rheumatoid arthritis-specific autoantibody and use thereof
JP2013506687A (ja) 2009-09-30 2013-02-28 プレジデント アンド フェロウズ オブ ハーバード カレッジ オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法
EP2492689B8 (en) 2011-02-22 2013-12-25 Bernhard-Nocht-Institut für Tropenmedizin Detection of antibodies using an improved immune complex (IC) ELISA
WO2013169382A1 (en) * 2012-05-07 2013-11-14 DePuy Synthes Products, LLC Methods and devices for treating intervertebral disc disease
EP2893041A4 (en) * 2012-09-05 2016-07-06 Bio Rad Laboratories CHIMERIC ANTI-DSDNA / CHROMATIN ANTIBODY
US10881720B2 (en) 2014-01-30 2021-01-05 The Board Of Regents Of The University Of Texas System Nanoparticles for immune stimulation
CN109712678B (zh) * 2018-12-12 2020-03-06 中国人民解放军军事科学院军事医学研究院 关系预测方法、装置及电子设备

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0559046A (ja) * 1991-06-26 1993-03-09 Ajinomoto Co Inc 免疫調節剤
ATE328890T1 (de) * 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP3472048B2 (ja) * 1995-10-09 2003-12-02 鐘淵化学工業株式会社 自己免疫疾患の診断薬
AU738513B2 (en) * 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1999001154A1 (en) 1997-07-03 1999-01-14 University Of Iowa Research Foundation Method for inhibiting immunostimulatory dna associated responses
DE69935507T2 (de) * 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1820514A3 (en) * 1998-06-15 2007-10-17 AltaRex Medical Corporation Therapeutic compositions that produce an immune response by altering the antigen
SK287400B6 (sk) 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
DE10083095D2 (de) * 1999-10-12 2002-01-31 Fritz Schwarzmann Gentransfervektoren zur Therapie von Autoimmunerkrankungen und Erkrankungen mit Immunpathogenese
GB9927332D0 (en) * 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
US20040023870A1 (en) * 2000-01-21 2004-02-05 Douglas Dedera Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
GB0001704D0 (en) * 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
JP5004261B2 (ja) * 2000-05-19 2012-08-22 コリクサ コーポレイション 単糖類及び二糖類に基づく化合物を用いた感染症及び他の疾患の予防的並びに治療的な処置
EP1296714B1 (en) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
CA2432542A1 (en) 2000-12-22 2002-07-04 Synovis Limited Methods of modulating toll-related receptor (trr) signaling
EP1412390A2 (en) 2001-07-26 2004-04-28 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9

Also Published As

Publication number Publication date
EP1435987A4 (en) 2005-11-23
EP1435987A1 (en) 2004-07-14
CA2459310A1 (en) 2003-03-20
EA200400407A1 (ru) 2004-08-26
WO2003022296A1 (en) 2003-03-20
US20100203053A1 (en) 2010-08-12
KR20040053122A (ko) 2004-06-23
IL160561A0 (en) 2004-07-25
CN1575184A (zh) 2005-02-02
US7709451B2 (en) 2010-05-04
US20050106142A1 (en) 2005-05-19
NZ531612A (en) 2006-01-27
JP2009203245A (ja) 2009-09-10
AU2002324937B2 (en) 2008-11-13
JP2005501917A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
BR0212366A (pt) Método e composição para tratar distúrbios associados com o complexo imune
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
Rodrigues et al. Co‐localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum
Martin‐Ruiz et al. α4 but not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease
Youn et al. Beneficial effects of rosmarinic acid on suppression of collagen induced arthritis.
CY1119122T1 (el) Θεραπευτικη αναπληρωση και εμπλουτισμος της λιπανσεως της οφθαλμικης επιφανειας
Hao et al. Garcinol upregulates GABAA and GAD65 expression, modulates BDNF-TrkB pathway to reduce seizures in pentylenetetrazole (PTZ)-induced epilepsy
Hruska et al. Estrogen treatment increases the density of D1 dopamine receptors in the rat striatum
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
BR9913347A (pt) Integração de desasfaltagem por solvente e gaseificação
BRPI0410876A (pt) molécula inibidora do complemento, anticorpo, proteìna de fusão, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar uma molécula inibidora do complemento ou um seu equivalente funcional ou uma proteìna de fusão, para identificar um ligando de uma molécula inibidora do complemento, ou um seu equivalente funcional, para tratar um animal que esteja sofrendo de uma doença ou um distúrbio mediados pelo complemento, ou prevenir que um aninal desenvolva uma doença ou um disturbio mediados pelo complemento, para vacinar um animal contra uma doença ou um distúrbio transmitidos por um artrópode hematófago e para inibir as vias do complemento clássica e alternativa em uma célula, tecido ou organismo não humano, composição, uso de uma molécula inibidora do complemento, uma proteìna de fusão ou uma molécula de ácido nucleico
BRPI0410927A (pt) métodos terapêuticos e profiláticos para distúrbios neuromusculares
BRPI0412890A (pt) método de tratar uma doença em um indivìduo humano em necessidade do mesmo, composição farmacêutica, e, métodos de selecionar um composto para administração conjuntamente com um anticorpo terapêutico, e de aumentar a eficiência de um tratamento envolvendo a administração de um anticorpo terapêutico que pode ser ligado por cd16 em um indivìduo
Miller Expression of transforming growth factor‐β in developing rat cerebral cortex: Effects of prenatal exposure to ethanol
Chen et al. The effect of cholinergic manipulations on the analgesic response to cobrotoxin in mice
BR0214716A (pt) Contraceptivos para prevenção de gravidez e diminuição de sintomatologia pré-menstrual
BR9813256A (pt) Composto, composição farmacêutica, e, processos para tratar de um paciente com uma doença neurodegenerativa, para prevenir o inìcio de uma doença neurodegenerativa em um paciente, para tratar de um paciente com uma doença autoimune, para prevenir o inìcio de uma doença autoimune em um paciente, para tratar de um paciente com uma doença inflamatória e para prevenir o inìcio de uma doença inflamatória em um paciente
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
Kallweit et al. Glutamine prevents apoptosis in intestinal epithelial cells and induces differential protective pathways in heat and oxidant injury models
BR0215588A (pt) Compostos imunoefetores
BR0010515A (pt) Sistema terapêutico de ministração transdérmica, processo para mascarar um odor desagrádavel e uso de um óleo essencial em um sistema terapéutico de ministração transdérmica
Cavun et al. CDP‐choline increases plasma ACTH and potentiates the stimulated release of GH, TSH and LH: the cholinergic involvement
Olivero et al. Immuno‐pharmacological characterization of group II metabotropic glutamate receptors controlling glutamate exocytosis in mouse cortex and spinal cord
DK0482089T3 (da) Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]